ReviewAmerican journal of ophthalmology2020
Retinopathy of Prematurity: Evolving Treatment With Anti-Vascular Endothelial Growth Factor.
Review in American journal of ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.International ophthalmology · 2023Pooled it
- Analgesia for retinopathy of prematurity screening: A systematic review.Pain practice : the official journal of World Institute of Pain · 2022Pooled it
- Airway management and postoperative respiratory recovery after intravitreal injection in preterm infants.Pediatric research · 2026Article
- Coronary endothelial cells undergo venous-enriched disrupted maturation following myocardial infarction.Basic research in cardiology · 2026Article
- Polyunsaturated Fatty Acid Balance Modulates Microglial State in a Murine Model of Oxygen-Induced Neovascularization.Nutrients · 2026Article
- OCT-Derived Quantitative Measurement of Extent of Vascularization ("Zone") in Retinopathy of Prematurity.Ophthalmology science · 2026Article
- Beyond transcription: RNA-binding proteins steering angiogenesis.American journal of physiology. Heart and circulatory physiology · 2026Review
- Polyunsaturated fatty acid balance modulates microglial state in a murine model of oxygen-induced neovascularization.Research square · 2025Article
- Robo4 inhibits neovascularization in oxygen-induced retinopathy by regulating ARF6 and VEGF.Human cell · 2025Article
- MAP4K4 aggravates microvascular anomalies in diabetic retinopathy in a YTHDF2-dependent manner.Diabetologia · 2025Article
- Prediction of Reactivation After Antivascular Endothelial Growth Factor Monotherapy for Retinopathy of Prematurity: Multimodal Machine Learning Model Study.Journal of medical Internet research · 2025Article
- Curcumin inhibits ferroptosis-mediated vascular occlusion by regulating the CXCL10/CXCR3 axis in retinopathy of prematurity.Molecular medicine (Cambridge, Mass.) · 2025Article
- Ref-1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF-1α.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- OCTA-based evaluation of the correlation between macular retinal and choroidal structural characteristics and refractive status in patients with retinopathy of prematurity.Frontiers in pediatrics · 2025Article
- The Ability of Large Language Models to Generate Patient Information Materials for Retinopathy of Prematurity: Evaluation of Readability, Accuracy, and Comprehensiveness.Turkish journal of ophthalmology · 2024Article
- Long-term follow-up of the cognitive function in children after intravitreal ranibizumab for retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Anti-Vascular Endothelial Growth Factor (Anti-VEGF) for the Treatment of Type I ROP.Indian journal of pediatrics · 2024Article
- Article
- Epithelial Membrane Protein 2 (EMP2) Blockade Attenuates Pathological Neovascularization in Murine Oxygen-Induced Retinopathy.Investigative ophthalmology & visual science · 2024Article
- Non-surgical treatment of stage 4A retinopathy of prematurity.BMC ophthalmology · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purposeTo discuss the evolution in retinopathy of prematurity since its first description as retrolental fibroplasia in the United States, including the changes in the understanding of pathophysiology; methods of diagnosis; destructive, anti-vascular endothelial growth factor (anti-VEGF), and supportive treatments; and differences in retinopathy of prematurity manifestations worldwide. The overall goal is to clarify retinopathy of prematurity currently and formulate questions to optimize future care. STUDY
designLiterature review and synthesis.
methodsCritical review and consideration of the literature with inclusion of historical articles and those regarding pathophysiologic risk factors, retinopathy of prematurity worldwide, basic and clinical science particularly regarding anti-VEGF mechanisms and agents tested in clinical trials.
resultsRetinopathy of prematurity has evolved from affecting infants approximately 2 months premature to affecting extremely premature infants. Worldwide, retinopathy of prematurity differs and, in emerging countries, has features similar to that experienced in the United States when retinopathy of prematurity first manifested. Treatments have evolved from destruction of the peripheral avascular retina to inhibit angiogenic stimuli to anti-VEGF agents, which inhibit pathologic angiogenesis but also extend normal intraretinal angiogenesis by ordering the development of intraretinal vessels. Clinical trial evidence is accruing with the goal to develop less destructive treatments to optimize vision and that are protective to the retina and infant.
conclusionsGoals for retinopathy of prematurity are to optimize prenatal and perinatal care, improve diagnostic acumen worldwide and refine treatment strategies, including with anti-VEGF agents, to inhibit intravitreal angiogenesis and facilitate vascularization of the previously avascular retina, which include supporting neural and vascular development of the premature infant and retina.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.